HOME >> BIOLOGY >> NEWS
Experimental Staph Vaccine Broadly Protective In Animal Studies

Researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID) have developed a vaccine that protects mice against multiple strains of Staphylococcus aureus (S. aureus), an increasingly stubborn microbe and the most common cause of hospital-acquired infections. The new vaccine is the first to be made from a bacterial molecule produced primarily during infection, rather than in laboratory culture. A report of the study by scientists at Brigham and Women's Hospital and Harvard Medical School in Boston appears in the May 28, 1999, issue of Science.

"This is an intriguing finding and a hopeful step against a very worrisome pathogen," says NIAID Director Anthony S. Fauci, M.D. "Within the last two years, S. aureus has become increasingly resistant to antibiotics. Most troubling is the emergence of strains that are partially resistant to vancomycin, our last line of defense against S. aureus. New treatments and, ideally, an effective vaccine, are urgently needed."

Each year an estimated 500,000 patients in American hospitals contract staph infections. S. aureus, the chief culprit, also is a common source of community acquired infections, and causes illnesses that range from minor skin infections and abscesses to life-threatening diseases such as severe pneumonia, meningitis, bone and joint infections, and infections of the heart and bloodstream.

Molecules isolated from bacteria grown in the laboratory have been one source of new vaccine candidates. However, since bacterial growth under laboratory conditions may not mimic an actual infection, scientists recently have begun searching for bacterial products that are activated specifically during infection.

"Presumably, these products are critical for infection and disease progression, and would therefore be logical targets for new therapeutics or vaccines," explains Gerald B. Pier, Ph.D., who led the research team that developed the new S. aureus vaccine.

The resear
'"/>

Contact: John Bowersox
jbowersox@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
28-May-1999


Page: 1 2 3

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. Experimental therapy stops allergic reactions in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/6/2019)... ... August 06, 2019 , ... A ... system that could have far-reaching implications for personalized medicine, especially when seeking treatments ... is able to predict which stem cell donors and manipulation methods might yield ...
(Date:8/6/2019)... ... August 05, 2019 , ... Rigaku Corporation , a ... the Microscopy & Microanalysis 2019 Meeting ( M&M 2019 ), taking place August ... The Microscopy & Microanalysis Meeting, organized by the Microscopy Society of America, is ...
(Date:8/4/2019)... ... August 02, 2019 , ... Bioclinica, a leading ... advancing the development of medical therapies, announced today that Michael O’Neal, M.D., Chief ... of the “100 Most Inspiring People in the Life-Sciences Industry.” Dr. O’Neal ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... August 06, 2019 , ... The National ... launch of a community project that will engage middle and early high school ... entitled “A Youth-Led Citizen Science Network for Community Environmental Assessment.” Collaborative partners presenting ...
(Date:7/23/2019)... ... July 22, 2019 , ... While today Visikol is ... fields of 3D tissue imaging , digital pathology , 3D ... in 2013 as a products company. These products are focused on addressing the ...
(Date:7/17/2019)... ... July 16, 2019 , ... Catalent ... of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular ... dedicated manufacturing space at the new, state-of-the-art commercial manufacturing center near Baltimore-Washington ...
(Date:7/9/2019)... ... July 08, 2019 , ... Balluff has been ... recognized as the 2019 Innovative Product of the Year which highlights cutting-edge advancements ... during Sensors Expo & Conference 2019, held this week in San ...
Breaking Biology Technology:
Cached News: